2023
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?
Chehayeb R, Kahn A, Pusztai L. Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials? Future Oncology 2023, 19: 1945-1951. PMID: 37767612, DOI: 10.2217/fon-2022-1203.Peer-Reviewed Original ResearchExcellent long-term survivalNeoadjuvant breast cancer trialsResidual cancer burden scorePathologic complete responseBreast cancer trialsLong-term survivalNeoadjuvant chemotherapyPathologic responseComplete responseSurvival improvementBurden scoreResidual diseaseTrial armsSurvival differencesCancer trialsBreast cancerTreatment efficacyStage IIGood surrogateEfficacy scoresTrialsSurvivalScoresRate differencesChemotherapy
2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst G, Bedrosian I, Layman R, Carter J, Klein M, Venters S, Shad S, van der Noordaa M, Chien A, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu M, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Veer L, Valero V, Esserman L, Symmans W. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy. Annals Of Oncology 2021, 32: 642-651. PMID: 33617937, DOI: 10.1016/j.annonc.2021.02.011.Peer-Reviewed Original ResearchConceptsResidual cancer burdenI-SPY2 trialIndependent prognostic informationPrognostic informationBreast cancerPrognostic signaturePre-treatment tumor biopsiesHER2-negative breast cancerStage IIDistant relapse-free survivalMultivariate Cox regression modelHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Chemo-endocrine therapyEndocrine-based treatmentAdjuvant endocrine therapyGrowth factor receptor 2Primary outcome measureRelapse-free survivalSimilar prognostic informationCox regression modelMolecular prognostic signaturesNegative breast cancerFactor receptor 2MDACC cohort
2017
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals Of Oncology 2017, 28: 2420-2428. PMID: 28961844, PMCID: PMC5834134, DOI: 10.1093/annonc/mdx397.Peer-Reviewed Original ResearchConceptsHER2-negative primary breast cancerAdjuvant hormonal therapyPrimary breast cancerTriple-negative breast cancerEstrogen receptor positivityHormonal therapyBreast cancerER expressionNeoadjuvant chemotherapyOverall survivalReceptor positivityPathological complete response rateHER2-negative breast cancerStage IIHuman epidermal growth factor 2Better long-term outcomesEpidermal growth factor 2Complete response rateProgesterone receptor expressionLong-term outcomesNegative breast cancerTerms of pCRLogistic regression modelsDefinitive surgeryGrowth factor 2
2008
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. British Journal Of Cancer 2008, 99: 68-71. PMID: 18560403, PMCID: PMC2453019, DOI: 10.1038/sj.bjc.6604443.Peer-Reviewed Original ResearchConceptsCollagen IV levelsHealthy womenCancer patientsBreast cancerPreoperative chemotherapySerum levelsCollagen IVBaseline serum levelsSerum collagen IVPrimary breast cancerBreast cancer patientsSera of patientsMarkers of angiogenesisSandwich enzyme-linked immunoassayEnzyme-linked immunoassayCollagen IV concentrationVascular basement membraneClinical stageHER2 statusHealthy controlsSignificant further increaseHealthy volunteersPatientsChemotherapyStage IIPredictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays
Zoubir M, Mathieu M, Liedtke C, Bidard F, Delaloge S, Corley L, Spielmann M, Pusztai L, André F, Symmans W. Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays. Journal Of Clinical Oncology 2008, 26: 560-560. DOI: 10.1200/jco.2008.26.15_suppl.560.Peer-Reviewed Original ResearchPIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer. Breast Cancer Research 2008, 10: r27. PMID: 18371219, PMCID: PMC2397526, DOI: 10.1186/bcr1984.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClass I Phosphatidylinositol 3-KinasesDNA Mutational AnalysisFemaleHumansLymphatic MetastasisMiddle AgedMutationNeoadjuvant TherapyNeoplasm StagingPhosphatidylinositol 3-KinasesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTaxoidsConceptsPathological complete responseER-positive tumorsPIK3CA mutationsBreast cancerChemotherapy sensitivityPIK3CA exon 9 mutationsStage IIResidual cancer burden scoreER-negative breast tumorsReceptor expression statusNode-positive diseaseResultsTwenty-three patientsTaxane-based chemotherapyType of chemotherapyNode-positive tumorsPIK3CA-activating mutationsEstrogen receptor (ER) expression statusExon 9 mutationsPIK3CA activationRCB scoreChemotherapy regimenNeoadjuvant chemotherapyComplete responseResidual cancerER status
2007
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Research 2007, 9: r87. PMID: 18086299, PMCID: PMC2246190, DOI: 10.1186/bcr1836.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, Fine-NeedleBreast NeoplasmsCD40 AntigensCyclophosphamideEpirubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoadjuvant TherapyNeoplasm StagingNeoplasm, ResidualPaclitaxelPredictive Value of TestsReceptor, ErbB-2RNA, MessengerSignal TransductionTranscription, GeneticTrastuzumabTreatment OutcomeUp-RegulationConceptsPathologic complete responseBreast cancerIIIA breast cancerFine-needle aspirationConcomitant paclitaxelConcomitant trastuzumabFEC therapyPreoperative trastuzumabPreoperative chemotherapyPrimary endpointComplete responseNodal statusResidual cancerTumor sizeTumor responseNuclear gradeReceptor mRNAMolecular predictorsTrastuzumabStage IIGreater riskLow expressionCancerCyclophosphamidePatients
2004
Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma
Gonzalez‐Angulo A, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004, 101: 258-263. PMID: 15241821, DOI: 10.1002/cncr.20348.Peer-Reviewed Original ResearchConceptsEarly-stage breast carcinomaBreast carcinomaTumor specimensPathologic responseStage II breast carcinomaAJCC stage IIMedian patient ageStage III diseasePathologic complete responseOverall survival rateLack of associationGene amplificationPreoperative chemotherapyRecurrent diseaseComplete responsePatient agePatientsCarcinomaSurvival rateTissue specimensStage IITaxanesHormone receptorsTumorsDisease
2003
Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse
Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse. Breast Cancer Research And Treatment 2003, 78: 105-118. PMID: 12611463, DOI: 10.1023/a:1022166517963.Peer-Reviewed Original ResearchConceptsER-negative statusER-positive tumorsSite of recurrenceBreast cancer deathsFirst recurrenceER statusTumor recurrenceCancer deathClinical behaviorAdjuvant therapy protocolsOperable stage IIER-negative cancersER-positive statusRate of recurrenceBreast cancer relapseHigh rateMenopausal statusTumor burdenRecurrence rateBreast cancerEstrogen receptorCancer relapseRecurrencePatientsStage II
2001
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma
Kuerer H, Singletary S, Buzdar A, Ames F, Valero V, Buchholz T, Ross M, Pusztai L, Hortobagyi G, Hunt K. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. The American Journal Of Surgery 2001, 182: 601-608. PMID: 11839324, DOI: 10.1016/s0002-9610(01)00793-0.Peer-Reviewed Original ResearchConceptsLocal-regional recurrence rateOperable breast cancerPrimary tumorBreast cancerTumor downstagingNeoadjuvant chemotherapyResidual carcinomaRecurrence rateStage III breast carcinomaStage IIComplete clinical responseCycles of chemotherapyMedian tumor sizeAxillary node dissectionBreast conservation surgeryNode dissectionClinical responseProspective trialSurgical resectionPalpable massSegmental resectionAdequate resectionPathologic examinationTumor sizeLarge tumors